Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
McKesson
Baxter
Express Scripts
Harvard Business School

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR SECRETIN SYNTHETIC HUMAN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Secretin Synthetic Human

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00036231 ↗ Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction Terminated Repligen Corporation Phase 3 2002-04-01 The purpose of the study is to determine the effect of multiple doses of secretin on autism.
NCT00036244 ↗ Synthetic Human Secretin in Children With Autism Completed Repligen Corporation Phase 3 2002-04-01 The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
NCT00065962 ↗ Secretin for the Treatment of Autism Completed National Institute on Deafness and Other Communication Disorders (NIDCD) Phase 3 1999-06-01 Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00065962 ↗ Secretin for the Treatment of Autism Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 1999-06-01 Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Secretin Synthetic Human

Condition Name

Condition Name for Secretin Synthetic Human
Intervention Trials
Autism 3
Chronic Pancreatitis 2
Pancreatic Disease 1
Pancreatitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Secretin Synthetic Human
Intervention Trials
Pancreatitis 4
Autistic Disorder 3
Pancreatitis, Chronic 2
Compulsive Personality Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Secretin Synthetic Human

Trials by Country

Trials by Country for Secretin Synthetic Human
Location Trials
United States 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Secretin Synthetic Human
Location Trials
Massachusetts 4
Indiana 2
Colorado 2
Washington 2
Utah 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Secretin Synthetic Human

Clinical Trial Phase

Clinical Trial Phase for Secretin Synthetic Human
Clinical Trial Phase Trials
Phase 3 5
Phase 2 2
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Secretin Synthetic Human
Clinical Trial Phase Trials
Completed 5
Terminated 4
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Secretin Synthetic Human

Sponsor Name

Sponsor Name for Secretin Synthetic Human
Sponsor Trials
Repligen Corporation 4
Massachusetts General Hospital 3
ChiRhoClin, Inc. 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Secretin Synthetic Human
Sponsor Trials
Industry 6
Other 6
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Dow
Colorcon
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.